Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sagittarius Life Science (ROCO:3205) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sagittarius Life Science EBITDA Margin % Related Terms
Sagittarius Life Science EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3205 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Sagittarius Life Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagittarius Life Science EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagittarius Life Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sagittarius Life Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagittarius Life Science (ROCO:3205) has a EBITDA Margin % of -24.77% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sagittarius Life Science and its competitors. According to the industry distribution chart, Sagittarius Life Science ranks #356 out of 939 companies in the Biotechnology industry, placing it in the top 37.9%.
Is Sagittarius Life Science's EBITDA Margin % too high?
Sagittarius Life Science's current EBITDA Margin % is -24.77%. Based on the distribution chart, Sagittarius Life Science ranks #356 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagittarius Life Science has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagittarius Life Science's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sagittarius Life Science ranks #356 out of 939 companies for EBITDA Margin %. This puts Sagittarius Life Science in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sagittarius Life Science and its competitors. Sagittarius Life Science's current EBITDA Margin % is -24.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagittarius Life Science stock overvalued right now?
Based on GuruFocus' analysis, Sagittarius Life Science (ROCO:3205) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$17.93, compared to a current price of NT$50.20 — trading 180% above its estimated fair value. The current EBITDA Margin % is -24.77%. Sagittarius Life Science's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sagittarius Life Science (ROCO:3205), the current EBITDA Margin % is -24.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sagittarius Life Science (ROCO:3205) Overvalued in 2026?
Based on GuruFocus' analysis, Sagittarius Life Science stock appears to be overvalued.
The current stock price of NT$50.20 is trading 180% above its estimated GF Value™ of NT$17.93.
GuruFocus considers Sagittarius Life Science to be Significantly Overvalued.
Key valuation signals for ROCO:3205:
EBITDA Margin %: -24.77%
GF Value™: NT$17.93 vs. price of NT$50.20 (180% above fair value)
No single metric tells the full story. See the ROCO:3205 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagittarius Life Science Corp is a Taiwan-based company engaged in the biotechnology and pharmaceutical sectors. The segment includes: Food and Others, with the majority of revenue from Food.
47GF Score
Get the complete analysis for ROCO:3205
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3205 has been successfully added to your 
